文献速递主动脉疾病内脏/肾动脉与血管畸形

WeFlow-JAAA覆膜支架系统治疗近肾腹主动脉瘤的首次人体临床试验

First-in-Human Clinical Trial of the WeFlow-JAAA Endograft System in Patients With Juxtarenal Abdominal Aortic Aneurysms.
PubMed 文献 · J Endovasc Ther · 2023-11-24

OBJECTIVE: To preliminarily evaluate the safety and efficacy of the WeFlow-JAAA endograft, a novel off-the-shelf device designed for the repair of juxtarenal abdominal aortic aneurysms (JRAAAs) and pararenal abdominal aortic aneurysms (PRAAAs).…

要点

  • 随访期间无主动脉相关死亡、破裂、I型或III型内漏或开放手术转换。
  • 仅1例于术后14个月出现右肾动脉支架闭塞并需二次干预。

核心结论

  • WeFlow-JAAA覆膜支架系统在肾下锚定区≤10 mm的近肾腹主动脉瘤或肠系膜上动脉下方有至少5 mm锚定区的肾旁腹主动脉瘤患者中初步显示安全有效。
  • 作者指出正在中国开展大规模、多中心、前瞻性长期随访研究以验证上述发现。

研究设计与样本

  • 前瞻性单臂首次人体临床试验,2019年10月至2021年8月纳入15例近肾腹主动脉瘤(肾下锚定区≤10 mm)或肾旁腹主动脉瘤(肠系膜上动脉下方至少5 mm锚定区)患者。
  • 15例均为男性,平均年龄68.5±6.0岁,肾下锚定区长度中位数0 mm(IQR 0-4 mm)。
  • 装置设计:腹腔干采用宽扇形开窗,双肾动脉采用2个标准内分支,肠系膜上动脉采用「迷你内袖」加强开窗。
  • 主要疗效终点为12个月临床成功,主要安全终点为术后30天内无主要不良事件。

主要发现

  • 技术成功15/15例,术后30天内无主要不良事件发生。
  • 平均透视时间73.1±27.8分钟,平均对比剂用量130.7±29.4 mL。
  • 12个月时全部患者维持临床成功。
  • 随访期间无主动脉相关死亡、动脉瘤破裂、I型或III型内漏或开放手术转换。
  • 仅1例于术后14个月出现右肾动脉支架闭塞并需二次干预。

局限性

  • 原文结论指出需大规模、多中心、前瞻性长期随访研究验证上述发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To preliminarily evaluate the safety and efficacy of the WeFlow-JAAA endograft, a novel off-the-shelf device designed for the repair of juxtarenal abdominal aortic aneurysms (JRAAAs) and pararenal abdominal aortic aneurysms (PRAAAs). METHODS: This prospective single-arm first-in-human clinical trial included patients with JRAAAs (infrarenal necks ≤10 mm) or PRAAAs with at least a 5 mm sealing zone below the superior mesenteric artery (SMA) who underwent endovascular repair using the WeFlow-JAAA endograft system. With this system, the celiac artery was addressed with a wide scallop, the renal arteries (RAs) were addressed with 2 standard inner branches, and the SMA was addressed with a "mini-inner-cuff" reinforced fenestration. The primary efficacy endpoint was the clinical success at 12 months. The primary safety endpoint was the freedom from major adverse events (MAEs) in the first 30 days after surgery. RESULTS: Fifteen patients (all men; mean age 68.5±6.0 years) were enrolled between October 2019 and August 2021. The median infrarenal neck length was 0 mm (IQR, 0-4 mm). Technical success was achieved in all patients. No MAEs occurred in the first 30 days. The mean fluoroscopy time was 73.1±27.8 minutes, and the mean volume of contrast media was 130.7±29.4 mL. Clinical success was maintained in all patients at 12 months. No aortic-related deaths, aneurysm rupture, type I or type III endoleak, or open surgery conversion occurred during the follow-up period. The secondary intervention was required only in 1 patient who developed an occluded right RA stent 14 months after the procedure. CONCLUSION: The WeFlow-JAAA endograft device appears to be safe and efficacious in selected patients with JRAAAs or PRAAAs with more than 5 mm sealing zone below SMA. Large-scale, multicenter, and prospective studies with long-term follow-ups are ongoing to validate our findings in China. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT04745546 (URL: Guo's Visceral Arteries Reconstruction: The First in Man Study of WeFlow-JAAA Stent Graft System-Full-Text View-ClinicalTrials.gov)Clinical ImpactThe first-in-human clinical trial of the WeFlow-JAAA endograft system demonstrates promising safety and efficacy in treating juxtarenal abdominal aortic aneurysms (JRAAAs) and partial pararenal abdominal aortic aneurysms (PRAAAs). This innovative off-the-shelf device offers a potential alternative to traditional endovascular aortic repair. The successful outcomes, including technical success in all patients, freedom from major adverse events, and maintenance of clinical success at 12 months, suggest a potential shift in clinical practice towards using the WeFlow-JAAA endograft system for selected patients. This study paves the way for larger-scale, multicenter, prospective studies to further validate its long-term safety and efficacy, offering clinicians a new option for managing complex abdominal aortic aneurysms.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Gao JP, Zhang HP, Xiong J, et al. First-in-Human Clinical Trial of the WeFlow-JAAA Endograft System in Patients With Juxtarenal Abdominal Aortic Aneurysms. J Endovasc Ther. 2023. PMID: 37997684. doi:10.1177/15266028231210480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。